It is worth noting that PARPi treatment is not currently recommended by any regulatory agency guidelines for breast cancer with ATM2 and CHEK2. Our study is also limited based on the clinical and molecular (e.g., ER status) available in the CGP cohort. The gene discussed is CHEK2; the disease is breast carcinoma.